Clinical trialPhase 2Terminated
Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin
An Open Label, Multicenter, Single Arm Study of Pasireotide LAR in Patients With Rare Tumors of Neuroendocrine Origin
- Outcome
- Stopped earlySlow recruitment rate into this study with rare tumors of neuroendocrine origin (enrollment issues) (Enrollment)
- Phase
- Phase 2
- Status
- Terminated
- Study type
- Interventional
- Start
- September 2009
- Expected end
- June 2015
- Enrollment
- 118 participants
- Sites
- 42
- Primary outcomes
- Percentage of Responders at Month 6 - Pooled Pancreatic NETs (PNETs)
- Sponsor
- Industry
- Results posted
- 2016-07-26
- Last update
- 26 July 2016
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
This study will assess the effectiveness and safety of pasireotide long-acting release in patients who have rare tumors of neuroendocrine origin.
Posted results (ClinicalTrials.gov registry) · primary outcome public domain (ClinicalTrials.gov)
Percentage of Responders at Month 6 - Pooled Pancreatic NETs (PNETs) [6 months]. Number, percentage of participants. Gastrinoma (n=13): 46.2; VIpoma (n=2): 0.0; Glucagonoma (n=5): 0.0.
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Percentage of Responders at Month 6 - Individual NETs [6 months]. Number, percentage of participants. Gastrinoma (n=13): 46.2; Prolactinoma (n=37): 21.6; Nelson's Syndrome (n=14): 50.0.
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Percentage of Responders With Probability of Success at Month 6 - Individual NETs [6 months]. Number, Percentage of participants. Gastrinoma (n=13): 46.2; Prolactinoma (n=37): 21.6; Nelson's Syndrome (n=14): 50.0.
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
PNETs: Number of Patients Attaining Normalization or a More Than 50% Reduction in Primary Biochemical Tumor Marker [Baseline, month 6]. Number, Participants. Baseline: All PNETS (Gastrinoma) (n=20): 8. Month 6: All PNETS (Gastrinoma) (n=20): 5.
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
PiNETs: Number of Patients Attaining Normalization or a More Than 50% Reduction in Primary Biochemical Tumor Marker [Baseline, month 6]. Number, Participants. Baseline: All PiNETS (Prolactinoma) (n=39): 7. Month 6: All PiNETS (Prolactinoma) (n=39): 9.
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Nelson's Syndrome: Number of Patients Attaining Normalization or a More Than 50% Reduction in Primary Biochemical Tumor Marker [Baseline, month 6]. Number, Participants. Baseline: Nelson's Syndrome (n=14): 6. Month 6: Nelson's Syndrome (n=14): 6.